Related Experiment Video
Updated: Jul 31, 2026
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Secure reversal of immune evasion from refractory NSCLC and highly contagious CoV-2 mutants by using 3D-engineered
Yanna Zhang1,2, Qian Li2, Nanxi Liu2
1Department of Blood Transfusion, Sichuan Provincial People's Hospital University of Electronic Science and Technology of China Chengdu Sichuan China.
Abstract:
There is an imperative choice to develop a secure feasible strategy to address evasion dynamics of refractory tumors and SARS-CoV-2-variants, while stem cell-based protocol may be more reliable as its unique ability for resetting multifunctional immunity to address progressive tumor and the constantly-evolving virus. In this study, spheroid-embryonoid stem cells from mature somatic cells were engineered as multifunctional biologics (3D-E/BSC) and inoculated in senile rhesus to identify secure potential against immune-evasion from viral-variants. Meanwhile, a cohort of eligible patients with stage IV NSCLC were approved for phase I clinical trials. Subsequently, long-lasting security and efficacy were validated by primate and clinical trials (p < 0.01) in that it could not only stimulate serological immunity, but also reset core immunity for hosts to address variant evasion after 3D-E/BSC withdrawal. Particularly, illustrated by single-cell evolving trajectory, 3D-E/BSC had securely reset senile thymus of aging hosts to remodel core immunity by rearranging naive rhythm to evolve TRGC2+/JCHAIN+NKT clusters to abolish tumoral and viral evasion dynamics with path-feedbacks of NSCLC and COVID-19 simultaneously activated, leading to continuous blockade of breakthrough infection of viral-mutants and long-term survival in one-third of terminal patients without adjuvant required. Our study may pioneer a practical multifunctional strategy to eliminate evasion of SARS-CoV-2 variants and refractory NSCLC so as for victims to restart a new life-equation.
Insights
This study introduces 3D-E/BSC, a stem cell therapy that resets immunity to combat tumor evasion and SARS-CoV-2 variants. It shows promise in resetting core immunity, blocking infections, and improving survival in advanced NSCLC patients.
Area of Science:
- Immunology
- Regenerative Medicine
- Oncology
- Virology
Background:
- Refractory tumors and evolving viruses like SARS-CoV-2 present significant immune evasion challenges.
- Stem cell-based protocols offer a potential strategy for resetting multifunctional immunity against progressive diseases.
Purpose of the Study:
- To engineer spheroid-embryonoid stem cells (3D-E/BSC) as multifunctional biologics.
- To evaluate the security and efficacy of 3D-E/BSC in addressing immune evasion by viral variants and refractory tumors.
Main Methods:
- Engineering spheroid-embryonoid stem cells from mature somatic cells into 3D-E/BSC.
- Inoculating senile rhesus monkeys and conducting Phase I clinical trials in patients with stage IV NSCLC.
- Analyzing single-cell evolving trajectories to understand immune system remodeling.
Main Results:
- 3D-E/BSC demonstrated long-lasting security and efficacy in primate and clinical trials (p < 0.01).
- The therapy stimulated serological immunity and reset core immunity, enabling hosts to address variant evasion post-treatment.
- Resetting of the senile thymus by 3D-E/BSC led to the evolution of TRGC2+/JCHAIN+ NKT clusters, abolishing tumoral and viral evasion dynamics.
Conclusions:
- 3D-E/BSC offers a practical, multifunctional strategy to overcome immune evasion by SARS-CoV-2 variants and refractory NSCLC.
- The approach shows potential for continuous blockade of viral breakthrough infections and long-term survival in terminal cancer patients.
- This pioneering strategy may enable patients to overcome life-threatening conditions and restart their lives.
